Skip to content

Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis

Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01916005
Enrollment
174
Registered
2013-08-05
Start date
2014-02-05
Completion date
2023-04-21
Last updated
2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prosthetic Valve Endocarditis (PVE)

Brief summary

The diagnosis of prosthetic valve endocarditis (PVE) remains challenging. In PVE cases, initial echocardiography is normal or inconclusive in almost 30% of cases, leading to a decreased diagnostic accuracy for the modified Duke criteria. Aims: The investigators sought to determine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for diagnosing PVE. Methods: In two referral French centers (Timone Hospial, Marseille and Georges Pompidou European Hospital, Paris), the investigators plan to include consecutive patients suspected of having PVE. All of the patients will be subjected to clinical, microbiological, and echocardiographic evaluation. Cardiac PET/CT will be performed at admission and the data analysis will be based on visual interpretation and quantitative measurement of FDG uptake (SUVmax). The final diagnosis will be defined according to the clinical and/or pathological modified Duke criteria determined during a 3-month follow-up (gold standard).

Interventions

DEVICE18F-FDG PET/CT

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* unexplained persistent or recurrent fever \>38°C; * and/or unexplained increased serum C-reactive protein (CRP) level \>10 mg/L; and/or positive blood cultures, independent of the echocardiographic analysis results; * and/or positive serological testing for Coxiella burnetii, Bartonella spp., Mycoplasma pneumoniae, Legionella pneumophila, Aspergillus spp., or Tropheryma whipplei; * and/or a mass or a new partial prosthetic valve dehiscence observed using echocardiography.

Exclusion criteria

* pregnancy, * an inability to lie flat, * a need for urgent cardiac surgery, * hemodynamic instability, * cardiac surgery \<1 month ago, * and a blood glucose level \>1.8 g/L. Patients with a poor PET/CT image quality

Design outcomes

Primary

MeasureTime frameDescription
the diagnosis of prosthetic valve infective endocarditis39months18F-fluorodeoxyglucose positron emission tomography

Secondary

MeasureTime frameDescription
the reproducibility of the technique,39 monthsthe other diagnostic parameters of PET/CT (specificity and predictive values)
the comparison of the sensitivity of PET/CT with that of echocardiography,39 MONTHSthe other diagnostic parameters of PET/CT (specificity and predictive values)
the rate of detection of embolic events,39 MONTHSthe other diagnostic parameters of PET/CT (specificity and predictive values)
the prognostic value of the technique (death/valve surgery)39 MONTHSthe other diagnostic parameters of PET/CT (specificity and predictive values)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026